Clinical Research Directory

Inclusion Criteria: * Heart Failure with EF ≥ 40% (by TTE within last 3 months) * Mean Pulmonary Artery Pressure (mPAP) \>20 mmHg at rest * Pulmonary Vascular Resistance (PVR) ≥ 3WU at rest * Pulmonary Capillary Wedge Pressure \> 15 mmHg (at rest) or \> 18 with passive leg raise * Cardiac index (CI) ≥ 1.7 L/min/m2 * NYHA Class II or III * Glomerular Filtration Rate (GFR) ≥ 25 ml/min * N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥ 400pg/mL * Stable, guideline directed medical treatment, including controlled volume status for a minimum of 3 months prior treatment Exclusion Criteria: * Inability to take dual antiplatelet or anticoagulants, hypersensitivity or allergy to aspirin or clopidogrel * Pulmonary artery aneurysm, moderate or greater PA stenosis or other PA anatomy that would prevent safe or proper use of the study device * Systemic infection or localized infection/rash at planned access site at time of procedure * Myocardial infarction, unstable angina pectoris, or a cerebrovascular accident in the previous 3 months * CRT or other Interventional cardiac procedure (except RHC) within last 3 months * Any planned cardiac procedure or inpatient procedure within the next 30 days